Compare KALV & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALV | LWLG |
|---|---|---|
| Founded | N/A | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.7M | 578.6M |
| IPO Year | 2014 | 2011 |
| Metric | KALV | LWLG |
|---|---|---|
| Price | $15.48 | $6.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 721.4K | ★ 4.2M |
| Earning Date | 03-25-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000,000.00 | $95,605.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 495.66 | 136.05 |
| 52 Week Low | $9.83 | $0.79 |
| 52 Week High | $19.00 | $8.04 |
| Indicator | KALV | LWLG |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 63.80 |
| Support Level | $14.59 | $3.37 |
| Resistance Level | $16.49 | N/A |
| Average True Range (ATR) | 0.98 | 0.74 |
| MACD | -0.06 | 0.26 |
| Stochastic Oscillator | 13.35 | 66.07 |
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.